The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee (Q33732581)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

phase II clinical trial

0 references

7

object named as

Mark J Ratain

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Daniel J. Sargent

object named as

Daniel Sargent

3

1 reference

ORCID Public Data File 2021

author name string

Lesley Seymour

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

S Percy Ivy

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

David Spriggs

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Laurence Baker

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Larry Rubinstein

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Michael Le Blanc

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

David Stewart

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

John Crowley

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Susan Groshen

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jeffrey S Humphrey

12

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Pamela West

13

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Donald Berry

14

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

9 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1764-1769

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

GCP data quality for early clinical development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Issues in using progression-free survival when evaluating oncology products

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Considerations for the use of imaging tools for phase II treatment trials in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Randomized phase II designs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Effective incorporation of biomarkers into phase II trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Alternate endpoints for screening phase II studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Novel designs and end points for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Adaptive clinical trials: progress and challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Proposal for the use of progression-free survival in unblinded randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Design issues of randomized phase II trials and a proposal for phase II screening trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Randomized phase II designs in cancer clinical trials: current status and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

30 October 2018

Phase II trials in journal of clinical oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized discontinuation design: application to cytostatic antineoplastic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II stopping rules that employ response rates and early progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-09-3287

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33732581&oldid=1958996927"